Carol Reid

Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

C. Nicholas Hodge, Paul E. Aldrich, Lee T. Bacheler et al. · Chemistry & Biology · 1996 · 148 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +16

In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.

M. J. Otto, Sena Garber, Dean L. Winslow et al. · Proceedings of the National Academy of Sciences · 1993 · 129 citations

Life Sciences, Medicinal Chemistry, Molecular Biology +17

Potency of Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) Used in Combination with Other Human Immunodeficiency Virus NNRTIs, NRTIs, or Protease Inhibitors

Robert W. King, Ronald M. Klabe, Carol Reid et al. · Antimicrobial Agents and Chemotherapy · 2002 · 57 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266

Dean L. Winslow, Sena Garber, Carol Reid et al. · AIDS · 1996 · 54 citations

Life Sciences, Microbiology, Molecular Genetics +17

Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors

James D. Rodgers, Patrick Y. S. Lam, Barry L. Johnson et al. · Chemistry & Biology · 1998 · 39 citations · Full text

Pharmacy, Medicinal Chemistry, Molecular Biology +14